米力农治疗慢性充血性心力衰竭急性加重期的临床观察  

Clinical Observation of Milrinone in the Treatment of Chronic Congestive Heart Failure in Acute Exacerbation Stage

作　　者：贺淑媛[1,2] 李江林[1,2] 杨超[1,3] 叶喜阳[1,4] 

机构地区：[1]暨南大学第二临床医学院 [2]深圳市人民医院药学部,广东深圳518020 [3]深圳市人民医院心外科,广东深圳518020 [4]深圳市人民医院妇产科,广东深圳518020

出　　处：《中国药房》2015年第15期2075-2077,共3页China Pharmacy

摘　　要：目的:观察米力农治疗慢性充血性心力衰竭(CCHF)急性加重期的临床疗效和安全性。方法:将100例CCHF急性加重期患者随机均分为对照组和观察组。对照组患者给予血管紧张素转化酶抑制剂、β受体阻滞药、利尿药、醛固酮受体拮抗药、洋地黄等常规治疗。观察组患者在对照组治疗的基础上给予米力农0.3 mg/kg加入5%葡萄糖液注射液50 ml中,微量泵持续泵入,qd。两组患者疗程均为5 d。观察两组患者的临床疗效,治疗前后心脏指数(CI)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、心胸比率(CTR)、氨基末端B型利钠肽前体(NT-pro BNP)含量及不良反应发生情况。结果:两组患者总有效率比较差异无统计学意义(P>0.05)。治疗后,两组患者LVEDD、CTR均显著低于同组治疗前,差异均有统计学意义(P<0.01),但两组间比较差异无统计学意义(P>0.05);CI、LVEF均显著高于同组治疗前(P<0.01),且观察组高于对照组(P<0.05);NT-pro BNP显著低于同组治疗前(P<0.01),且观察组低于对照组(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:米力农治疗CCHF急性加重期的疗效和安全性与常规治疗相当,但在改善心功能方面优于常规治疗。OBJECTIVE：To observe the clinical efficacy and safety of milrinone in the treatment of chronic congestive heart failure（CCHF） in acute exacerbation stage.METHODS：100 patients with CCHF were randomly divided into control group and observation group.Patients in control group were given routine treatment,including angiotensinconverting enzyme inhibitors,βblockers,diuretics,aldosterone receptor antagonists and digitalis,etc.Based on the treatment of control group,patients in the observation group were given milrinone 0.3 mg/kg adding into 5% glucose injection 50 ml and it was continuously pumped with micro pump,once a day.The course of both was 5 d.The clinic data was observed,including clinical efficacy,CI,LVEDD,LVEF,CTR,NT-pro BNP before and after treatment and ADR.RESULTS：There were no significant difference in the clinical efficacy between 2 groups（P〉0.05）.After treatment,the LVEDD and CTR in 2 groups were significantly lower than before,with significant difference（P〈0.01）,but there was no significant difference between 2 groups（P〉0.05）.The CI and LVEF in 2 groups were significantly higher than before（P〈0.01）and observation group was higher than control group（P〈0.05）;the NT-pro BNP was significantly lower than before（P〈0.01）and observation group was lower than control group（P〈0.05）.There were no obvious adverse reactions during the treatment.CONCLUSIONS：Milrinone has similar efficacy and safety with routine treatment in the treatment of CCHF;however,it is better than routine treatment in improving the heart function.

关 键 词：米力农 慢性充血性心力衰竭 急性加重期 心功能 疗效 安全性 

分 类 号：R541.6[医药卫生—心血管疾病]